ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells

Leukemia. 2010 Apr;24(4):869-72. doi: 10.1038/leu.2009.300. Epub 2010 Jan 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Benzamides
  • Benzene Derivatives / pharmacology*
  • Cells, Cultured
  • Dasatinib
  • Drug Resistance, Neoplasm / drug effects*
  • Fusion Proteins, bcr-abl / antagonists & inhibitors*
  • Fusion Proteins, bcr-abl / genetics
  • Fusion Proteins, bcr-abl / metabolism
  • Humans
  • Imatinib Mesylate
  • Interleukin-3 / pharmacology
  • K562 Cells
  • Mice
  • Mutation / genetics
  • Phosphorylation / drug effects
  • Piperazines / pharmacology*
  • Precursor Cells, B-Lymphoid / drug effects*
  • Precursor Cells, B-Lymphoid / metabolism
  • Precursor Cells, B-Lymphoid / pathology
  • Protein Kinase Inhibitors / pharmacology*
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Protein-Tyrosine Kinases / genetics
  • Protein-Tyrosine Kinases / metabolism
  • Pyrimidines / pharmacology*
  • Thiazoles / pharmacology
  • Tyrosine / metabolism

Substances

  • Antineoplastic Agents
  • Benzamides
  • Benzene Derivatives
  • Interleukin-3
  • ON012380
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • Tyrosine
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl
  • Dasatinib